Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review)
- Authors:
- Mohd Adnan Kausar
- Sadaf Anwar
- Hemat El-Sayed El-Horany
- Farida Habib Khan
- Neetu Tyagi
- Mohammad Zeeshan Najm
- Sadaf
- Alaa Abdulaziz Eisa
- Chandrajeet Dhara
- Saumyatika Gantayat
-
Affiliations: Department of Biochemistry, College of Medicine, University of Ha'il, Ha'il 81411, Saudi Arabia, Medical and Diagnostic Research Centre, University of Ha'il, Hail 55473, Saudi Arabia, Bone Biology Laboratory, Department of Physiology, School of Medicine, University of Louisville, Louisville, KY, 40202, USA, School of Biosciences, Apeejay Stya University, Sohna, Gurugram 122003, Haryana, Department of Biotechnology, Jamia Millia Islamia, Okhla, New Delhi 110025, India, Department of Medical Laboratories Technology, College of Applied Medical Sciences, Taibah University, Medina 30002, Saudi Arabia - Published online on: October 10, 2023 https://doi.org/10.3892/ijo.2023.5578
- Article Number: 130
-
Copyright: © Kausar et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
National Cancer Institute: What is cancer? 2021, https://www.cancer.gov/about-cancer/understanding/what-is-cancer. | |
|
Blackadar CB: Historical review of the causes of cancer. World J Clin Oncol. 7:54–86. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK and Manyazewal T: New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 9:205031212110343662021. View Article : Google Scholar : PubMed/NCBI | |
|
Decker WK and Safdar A: Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 20:271–281. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, et al: Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun. 8:111–120. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg SA: IL-2: The first effective immunotherapy for human cancer. J Immunol. 192:5451–5458. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pierpont TM, Limper CB and Richards KL: Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy. Front Oncol. 8:163. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
June CH, O'Connor RS, Kawalekar OU, Ghassemi S and Milone MC: CAR T cell immunotherapy for human cancer. Science. 359:1361–1365. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gross G, Waks T and Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Graham C, Hewitson R, Pagliuca A and Benjamin R: Cancer immunotherapy with CAR-T cells-behold the future. Clin Med (Lond). 18:324–328. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Maus MV: A decade of CAR T cell evolution. Nat Cancer. 3:270–271. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, et al: Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 5:197ra1032013. View Article : Google Scholar : PubMed/NCBI | |
|
June CH, Riddell SR and Schumacher TN: Adoptive cellular therapy: A race to the finish line. Sci Transl Med. 7:280ps72015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YH and Kim CH: Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Arch Pharm Res. 42:607–616. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, Bulatov E and Rizvanov A: Advancing CAR T-cell therapy for solid tumors: Lessons learned from lymphoma treatment. Cancers (Basel). 12:1252020. View Article : Google Scholar : PubMed/NCBI | |
|
Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY and Zhao W: CAR-T design: Elements and their synergistic function. EBioMedicine. 58:1029312020. View Article : Google Scholar : PubMed/NCBI | |
|
Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO and Ploegh H: Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci USA. 116:7624–7631. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Barber A, Rynda A and Sentman CL: Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 183:6939–6947. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS and Powell DJ Jr: High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 30:1355–1364. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al: The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother. 28:203–211. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC and Riddell SR: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 3:125–135. 2015. View Article : Google Scholar | |
|
Zhang C, Liu J, Zhong JF and Zhang X: Engineering CAR-T cells. Biomark Res. 5:222017. View Article : Google Scholar : PubMed/NCBI | |
|
Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI | |
|
Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P and Ganguly N: CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 42:2183–2195. 2019.PubMed/NCBI | |
|
Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, Liu S and Ma J: CAR-T cell therapy in cancer: Tribulations and road ahead. J Immunol Res. 2020:19243792020. View Article : Google Scholar : PubMed/NCBI | |
|
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 118:6050–6056. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Duong CP, Yong CS, Kershaw MH, Slaney CY and Darcy PK: Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Mol Immunol. 67:46–57. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Qian L, Li D, Ma L, He T, Qi F, Shen J and Lu XA: The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Cell Immunol. 304:49–54. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, Kolbe C, Al Rawashdeh W, Brauner J, Hardt O, et al: Automated manufacturing of potent CD20-directed chimeric antigen receptor t cells for clinical use. Hum Gene Ther. 28:914–925. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M: Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 28:415–428. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hombach A, Hombach AA and Abken H: Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target'activation and unintended initiation of an innate immune response. Gene Ther. 17:1206–1213. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong XS, Matsushita M, Plotkin J, Riviere I and Sadelain M: Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 18:413–420. 2010. View Article : Google Scholar | |
|
Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, et al: Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 7:e14335182018. View Article : Google Scholar : PubMed/NCBI | |
|
Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, et al: A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 25:1003–1012. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM and Brenner MK: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Beatty GL and Moon EK: Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology. 3:e9700272014. View Article : Google Scholar | |
|
Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 15:1145–1154. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE and Gilham DE: CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics. 8:41–51. 2017. View Article : Google Scholar | |
|
John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH and Darcy PK: Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 19:5636–5646. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DW and Cho JY: Recent advances in allogeneic CAR-T cells. Biomolecules. 10:2632020. View Article : Google Scholar : PubMed/NCBI | |
|
Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD and Hirano N: A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 24:352–359. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dai H, Wang Y, Lu X and Han W: Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 108:djv4392016. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD and Wang W: Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 4:352019. View Article : Google Scholar : PubMed/NCBI | |
|
Levine BL, Miskin J, Wonnacott K and Keir C: Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 4:92–101. 2016. View Article : Google Scholar | |
|
Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S and Kobold S: Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 20:12832019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo S and Deng CX: Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 14:2083–2093. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, et al: XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. 35:290–300. 2016. View Article : Google Scholar | |
|
Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, Ochi T, Suzuki N, Fujiwara H, Ohara O, Shultz LD, et al: Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 127:722–734. 2016. View Article : Google Scholar : | |
|
Yin L and Wang XJ, Chen DX, Liu XN and Wang XJ: Humanized mouse model: A review on preclinical applications for cancer immunotherapy. Am J Cancer Res. 10:4568–4584. 2020. | |
|
Zitvogel L, Pitt JM, Daillère R, Smyth MJ and Kroemer G: Mouse models in on immunology. Nat Rev Cancer. 16:759–773. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, Krönke N, Feuerhake F, Ferreira de Figueiredo C, Blasczyk R, et al: CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics. 18:504–524. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jin CH, Xia J, Rafiq S, Huang X, Hu Z, Zhou X, Brentjens RJ and Yang YG: Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 39:173–181. 2019. View Article : Google Scholar : | |
|
Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, et al: Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice. Clin Cancer Res. 24:3981–3993. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar | |
|
Szöőr Á, Tóth G, Zsebik B, Szabó V, Eshhar Z, Abken H and Vereb G: Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484:1–8. 2020. View Article : Google Scholar | |
|
Liu Y, Zhou Y, Huang KH, Li Y, Fang X, An L, Wang F, Chen Q, Zhang Y, Shi A, et al: EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging (Albany NY). 11:11054–11072. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G and Fusco N: CAR-T cell therapy for triple-negative breast cancer and other solid tumors: Preclinical and clinical progress. Expert Opin Investig Drugs. 31:593–605. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei J, Sun H, Zhang A, Wu X, Li Y, Liu J, Duan Y, Xiao F, Wang H, Lv M, et al: A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Cell Immunol. 331:49–58. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wallstabe L, Mades A, Frenz S, Einsele H, Rader C and Hudecek M: CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models. Adv Cell Gene Ther. 1:e112018. View Article : Google Scholar | |
|
Zhao X, Qu J, Hui Y, Zhang H, Sun Y, Liu X, Zhao X, Zhao Z, Yang Q, Wang F and Zhang S: Clinicopathological and prognostic significance of c-Met overexpression in breast cancer. Oncotarget. 8:56758–56767. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Han Y, Xie W, Song DG and Powell DJ Jr: Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 11:922018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J and Mukherjee P: CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 10:11492019. View Article : Google Scholar : PubMed/NCBI | |
|
Wallstabe L, Göttlich C, Nelke LC, Kühnemundt J, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G, Nietzer SL and Hudecek M: ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 4:e1263452019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Li Y, Liu W and Li X: Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. Biomed Res Int. 2020:47951712020.PubMed/NCBI | |
|
Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, et al: In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. Int J Cancer. 146:236–247. 2020. View Article : Google Scholar | |
|
Song DG, Ye Q, Poussin M, Chacon JA, Figini M and Powell DJ Jr: Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 9:562016. View Article : Google Scholar : PubMed/NCBI | |
|
Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, et al: GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 9:16833452019. View Article : Google Scholar | |
|
Yang Y, Vedvyas Y, McCloskey JE, Min IM and Jin MM: ICAM-1 targeting CAR T cell therapy for triple negative breast cancer. Cancer Res. 79(13 Suppl): S23222019. View Article : Google Scholar | |
|
Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X and Wei F: CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 68:365–377. 2019. View Article : Google Scholar | |
|
Petrovic K, Robinson J, Whitworth K, Jinks E, Shaaban A and Lee SP: TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. PLoS One. 14:e02240152019. View Article : Google Scholar : PubMed/NCBI | |
|
Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, et al: TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res. 78:489–500. 2018. View Article : Google Scholar : | |
|
Bedoya DM, King T and Posey AD: Generation of CART cells targeting oncogenic TROP2 for the elimination of epithelial malignancies. Cytotherapy. 21(Suppl): S11–S12. 2019. View Article : Google Scholar | |
|
National Library of Medicine (NLM): Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma. ClinicalTrials.gov ID, NCT02208362. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/study/NCT02208362. | |
|
National Library of Medicine (NLM): CART-EGFRvIII + Pembrolizumab in GBM. ClinicalTrials.gov ID, NCT03726515. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03726515. | |
|
National Library of Medicine (NLM): GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression. ClinicalTrials.gov ID, NCT03198546. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03198546. | |
|
National Library of Medicine (NLM): Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma. ClinicalTrials.gov ID, NCT00902044. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT00902044. | |
|
National Library of Medicine (NLM): CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM). ClinicalTrials.gov ID, NCT01373047. NLM; Bethesda, MD: 2011, https://clinicaltrials.gov/ct2/show/NCT01373047. | |
|
National Library of Medicine (NLM): Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer. ClinicalTrials.gov ID, NCT01897415. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01897415. | |
|
National Library of Medicine (NLM): CAR T Cell Immunotherapy for Pancreatic Cancer. ClinicalTrials.gov ID, NCT03323944. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03323944. | |
|
National Library of Medicine (NLM): Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma. ClinicalTrials.gov ID, NCT03159819. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03159819. | |
|
National Library of Medicine (NLM): Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma. ClinicalTrials.gov ID, NCT03393936. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03393936. | |
|
National Library of Medicine (NLM): PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. ClinicalTrials.gov ID, NCT03873805. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03873805. | |
|
National Library of Medicine (NLM): CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer. ClinicalTrials.gov ID, NCT03089203. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03089203. | |
|
National Library of Medicine (NLM): Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*). ClinicalTrials.gov ID, NCT04020575. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04020575. | |
|
National Library of Medicine (NLM): MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. ClinicalTrials.gov ID, NCT03585764. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03585764. | |
|
National Library of Medicine (NLM): Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors. ClinicalTrials.gov ID, NCT02498912. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02498912. | |
|
National Library of Medicine (NLM): T-Cell Therapy for Advanced Breast Cancer. ClinicalTrials.gov ID, NCT02792114. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02792114. | |
|
National Library of Medicine (NLM): T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR). ClinicalTrials.gov ID, NCT02442297. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02442297. | |
|
National Library of Medicine (NLM): HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases. ClinicalTrials.gov ID, NCT03696030. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03696030. | |
|
National Library of Medicine (NLM): Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin. ClinicalTrials.gov ID, NCT02414269. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02414269. | |
|
National Library of Medicine (NLM): Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19. ClinicalTrials.gov ID, NCT01044069. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT01044069. | |
|
National Library of Medicine (NLM): Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19. ClinicalTrials.gov ID, NCT00466531. NLM; Bethesda, MD: 2007, https://clinicaltrials.gov/ct2/show/NCT00466531. | |
|
National Library of Medicine (NLM): CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH). ClinicalTrials.gov ID, NCT00586391. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00586391. | |
|
National Library of Medicine (NLM): CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH). ClinicalTrials.gov ID, NCT00608270. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00608270. | |
|
National Library of Medicine (NLM): Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies. ClinicalTrials.gov ID, NCT02315612. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT02315612. | |
|
National Library of Medicine (NLM): Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma. ClinicalTrials.gov ID, NCT01722149. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT01722149. | |
|
National Library of Medicine (NLM): Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01. ClinicalTrials.gov ID, NCT02311621. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT02311621. | |
|
National Library of Medicine (NLM): Study of bb21217 in Multiple Myeloma. ClinicalTrials.gov ID, NCT03274219. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03274219. | |
|
National Library of Medicine (NLM): Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL). ClinicalTrials.gov ID, NCT00881920. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00881920. | |
|
National Library of Medicine (NLM): KSafety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA). ClinicalTrials.gov ID, NCT03939026. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03939026. | |
|
National Library of Medicine (NLM): Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL. ClinicalTrials.gov ID, NCT03666000. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03666000. | |
|
National Library of Medicine (NLM): A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). ClinicalTrials.gov ID, NCT04035434. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04035434. | |
|
National Library of Medicine (NLM): Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMELI-01). ClinicalTrials.gov ID, NCT03190278. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03190278. | |
|
National Library of Medicine (NLM): Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). ClinicalTrials.gov ID, NCT04093596. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04093596. | |
|
National Library of Medicine (NLM): SaalloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK). ClinicalTrials.gov ID, NCT03692429. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03692429. | |
|
National Library of Medicine (NLM): Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC). ClinicalTrials.gov ID, NCT01140373. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT01140373. | |
|
National Library of Medicine (NLM): 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN). ClinicalTrials.gov ID, NCT01822652. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01822652. | |
|
National Library of Medicine (NLM): iC9-GD2-CARVZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (VEGAS). ClinicalTrials.gov ID, NCT01953900. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT01953900. | |
|
Almond LM, Charalampakis M, Ford SJ, Gourevitch D and Desai A: Myeloid sarcoma: Presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 17:263–267. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, et al: Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 25:285–295. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jain MD, Bachmeier CA, Phuoc VH and Chavez JC: Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. Ther Clin Risk Manag. 14:1007–1017. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, et al: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet. 396:839–852. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Abbott RC, Cross RS and Jenkins MR: Finding the keys to the CAR: Identifying novel target antigens for T cell redirection immunotherapies. Int J Mol Sci. 21:5152020. View Article : Google Scholar : PubMed/NCBI | |
|
Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al: Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 44:1444–1454. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S and Xu Y: CD19, from bench to bedside. Immunol Lett. 183:86–95. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al: Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 33:16882015. View Article : Google Scholar : PubMed/NCBI | |
|
Cortesi L, Rugo HS and Jackisch C: An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 16:255–282. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK and Tang H: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 22:1052023. View Article : Google Scholar : PubMed/NCBI | |
|
Schoninger SF and Blain SW: The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in breast cancer. Mol Cancer Ther. 19:3–12. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR, Manzella L and Vigneri P: AKT inhibitors: New weapons in the fight against breast cancer? Front Pharmacol. 12:6622322021. View Article : Google Scholar : PubMed/NCBI | |
|
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF and Schiff R: Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 17:233–250. 2020. View Article : Google Scholar | |
|
Tóth G, Szöllősi J, Abken H, Vereb G and Szöőr Á: A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts. Int J Mol Sci. 21:10392020. View Article : Google Scholar : PubMed/NCBI | |
|
Toulouie S, Johanning G and Shi Y: Chimeric antigen receptor T-cell immunotherapy in breast cancer: Development and challenges. J Cancer. 12:1212–1219. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI and Sang QA: Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer. 12:6949–6963. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rivas SR, Valdez MJM, Govindarajan V, Seetharam D, Doucet-O'Hare TT, Heiss JD and Shah AH: The role of HERV-K in cancer stemness. Viruses. 14:20192022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Rycaj K, Geng S, Li M, Plummer JB, Yin B, Liu H, Xu X, Zhang Y, Yan Y, et al: Expression of human endogenous retrovirus type K envelope protein is a novel candidate prognostic marker for human breast cancer. Genes Cancer. 2:914–922. 2011. View Article : Google Scholar | |
|
Pegram M and Slamon D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 27(Suppl 9): S13–S19. 2000. | |
|
Walsh EM, Keane MM, Wink DA, Callagy G and Glynn SA: Review of triple negative breast cancer and the impact of inducible nitric oxide synthase on tumor biology and patient outcomes. Crit Rev Oncog. 21:333–351. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tsutsui S, Ohno S, Murakami S, Hachitanda Y and Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 71:67–75. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nasiri F, Kazemi M, Mirarefin SMJ, Mahboubi Kancha M, Ahmadi Najafabadi M, Salem F, Dashti Shokoohi S, Evazi Bakhshi S and Safarzadeh Kozani P and Safarzadeh Kozani P: CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Front Immunol. 13:10187862022. View Article : Google Scholar : PubMed/NCBI | |
|
Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, et al: PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral sting pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9:722–737. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ternette N, Olde Nordkamp MJM, Müller J, Anderson AP, Nicastri A, Hill AVS, Kessler BM and Li D: Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics. 18:17004652018. View Article : Google Scholar : PubMed/NCBI | |
|
National Library of Medicine (NLM): Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection. ClinicalTrials.gov ID, NCT04164615. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04164615. | |
|
National Library of Medicine (NLM): Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer. ClinicalTrials.gov ID, NCT04329065. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04329065. | |
|
National Library of Medicine (NLM): Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab. ClinicalTrials.gov ID, NCT04276493. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04276493. | |
|
National Library of Medicine (NLM): Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection. ClinicalTrials.gov ID, NCT04170595. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04170595. | |
|
National Library of Medicine (NLM): A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases. ClinicalTrials.gov ID, NCT03500380. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03500380. | |
|
National Library of Medicine (NLM): Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2. ClinicalTrials.gov ID, NCT00019812. NLM; Bethesda, MD: 2003, https://clinicaltrials.gov/ct2/show/NCT00019812. | |
|
National Library of Medicine (NLM): Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT00003539. NLM; Bethesda, MD: 2004, https://clinicaltrials.gov/ct2/show/NCT00003539. | |
|
National Library of Medicine (NLM): Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT00006228. NLM; Bethesda, MD: 2003, https://clinicaltrials.gov/ct2/show/NCT00006228. | |
|
National Library of Medicine (NLM): Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2. ClinicalTrials.gov ID, NCT00003992. NLM; Bethesda, MD: 2004, https://clinicaltrials.gov/ct2/show/NCT00003992. | |
|
National Library of Medicine (NLM): Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02). ClinicalTrials.gov ID, NCT03571633. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03571633. | |
|
National Library of Medicine (NLM): A Study of Pertuzumab in Participants With Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT02491892. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02491892. | |
|
National Library of Medicine (NLM): Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab. ClinicalTrials.gov ID, NCT00301899. NLM; Bethesda, MD: 2006, https://clinicaltrials.gov/ct2/show/NCT00301899. | |
|
National Library of Medicine (NLM): A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT04924699. NLM; Bethesda, MD: 2021, https://clinicaltrials.gov/ct2/show/NCT04924699. | |
|
National Library of Medicine (NLM): ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03). ClinicalTrials.gov ID, NCT04829604. NLM; Bethesda, MD: 2021, https://clinicaltrials.gov/ct2/show/NCT04829604. | |
|
National Library of Medicine (NLM): Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour. ClinicalTrials.gov ID, NCT04107142. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04107142. | |
|
National Library of Medicine (NLM): A Study to Investigate LYL797 in Adults With Solid Tumors. ClinicalTrials.gov ID, NCT05274451. NLM; Bethesda, MD: 2022, https://clinicaltrials.gov/ct2/show/NCT05274451. | |
|
National Library of Medicine (NLM): A Biomarker Screening Protocol for Participants With Solid Tumors (START). ClinicalTrials.gov ID, NCT05891197. NLM; Bethesda, MD: 2023, https://clinicaltrials.gov/ct2/show/NCT05891197. | |
|
National Library of Medicine (NLM): cMet CAR RNA T Cells Targeting Breast Cancer. ClinicalTrials.gov ID, NCT01837602. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01837602. | |
|
National Library of Medicine (NLM): Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso. ClinicalTrials.gov ID, NCT02580747. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02580747. | |
|
National Library of Medicine (NLM): Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor. ClinicalTrials.gov ID, NCT02587689. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02587689. | |
|
National Library of Medicine (NLM): Multi-4SCAR-T Therapy Targeting Breast Cancer. ClinicalTrials.gov ID, NCT04430595. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04430595. | |
|
National Library of Medicine (NLM): EpCAM CAR-T for Treatment of Advanced Solid Tumors. ClinicalTrials.gov ID, NCT02915445. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02915445. | |
|
National Library of Medicine (NLM): C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N). ClinicalTrials.gov ID, NCT03635632. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03635632. | |
|
Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 3:160112016. View Article : Google Scholar : PubMed/NCBI | |
|
Almåsbak H, Aarvak T and Vemuri MC: CAR T cell therapy: A game changer in cancer treatment. J Immunol Res. 2016:54746022016. View Article : Google Scholar : PubMed/NCBI | |
|
Abreu TR, Fonseca NA, Gonçalves N and Moreira JN: Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 319:246–261. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH and Sherwin SA: Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 5:222017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, et al: Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 13:610–617. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121:5154–5157. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015. View Article : Google Scholar | |
|
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119:2709–2720. 2012. View Article : Google Scholar : | |
|
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5:177ra382013. View Article : Google Scholar : PubMed/NCBI | |
|
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Curran KJ, Pegram HJ and Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med. 14:405–415. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G and Oosterwijk E: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol. 24:e20–e22. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E and Pule M: Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods. 23:376–386. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, Cote DJ, Spendley L, Kim AH, Robertson MS, et al: Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 142:1334–1348. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Miao L, Zhang Z, Ren Z and Li Y: Reactions related to CAR-T cell therapy. Front Immunol. 12:6632012021. View Article : Google Scholar : PubMed/NCBI | |
|
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M and June CH: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 1:26–31. 2013. View Article : Google Scholar | |
|
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al: Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9053–9061. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH and Grupp SA: Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 22:1575–1586. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138:105–115. 2013. View Article : Google Scholar : | |
|
Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA and Kang CY: Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine. J Immunol. 182:1818–1828. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Davis RJ, Van Waes C and Allen CT: Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 58:59–70. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fedorov VD, Themeli M and Sadelain M: PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 5:215ra1722013. View Article : Google Scholar : PubMed/NCBI | |
|
Chmielewski M, Kopecky C, Hombach AA and Abken H: IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M and Brentjens RJ: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119:4133–4141. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S and Dholaria B: CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 3(Suppl 1): S24–S31. 2022. View Article : Google Scholar | |
|
Włodarczyk M and Pyrzynska B: CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer. Cancers (Basel). 15:1172022. View Article : Google Scholar | |
|
Hawkins ER, D'Souza RR and Klampatsa A: Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy. Biologics. 15:95–105. 2021.PubMed/NCBI | |
|
Rafiq S, Hackett CS and Brentjens RJ: Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 17:147–167. 2020. View Article : Google Scholar : | |
|
Xia L, Zheng Z, Liu JY, Chen YJ, Ding J, Hu GS, Hu YH, Liu S, Luo WX, Xia NS and Liu W: Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol Res. 9:707–722. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, et al: Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 20:1262021. View Article : Google Scholar : PubMed/NCBI | |
|
Yan T, Zhu L and Chen J: Current advances and challenges in CAR T-Cell therapy for solid tumors: Tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 12:142023. View Article : Google Scholar : PubMed/NCBI | |
|
Collins DC, Sundar R, Lim JSJ and Yap TA: Towards precision medicine in the clinic: From biomarker discovery to novel therapeutics. Trends Pharmacol Sci. 38:25–40. 2017. View Article : Google Scholar |
